Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 148 articles: HTML format

Single Articles

August 2022
1. DEBIK J, Schafer H, Andreassen T, Wang F, et al
   Lipoprotein and metabolite associations to breast cancer risk in the HUNT2 study.
   Br J Cancer. 2022 Aug 4. pii: 10.1038/s41416-022-01924.
   PubMed     Abstract available
   
   
   July 2022
2. SHU X, Zhou Q, Sun X, Flesaker M, et al
   Associations between circulating proteins and risk of breast cancer by intrinsic subtypes: a Mendelian randomisation analysis.
   Br J Cancer. 2022 Jul 26. pii: 10.1038/s41416-022-01923.
   PubMed     Abstract available
   
   
   
3. VAN DEN BOSCH T, Rueda OM, Caldas C, Vermeulen L, et al
   Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy.
   Br J Cancer. 2022 Jul 21. pii: 10.1038/s41416-022-01906.
   PubMed     Abstract available
   
   
   
4. LI T, Houssami N, Noguchi N, Zeng A, et al
   Differential detection by breast density for digital breast tomosynthesis versus digital mammography population screening: a systematic review and meta-analysis.
   Br J Cancer. 2022;127:116-125.
   PubMed     Abstract available
   
   
   
5. ALLEN V, Coulombe J, Zhao H, Kreps LM, et al
   VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models.
   Br J Cancer. 2022;127:56-68.
   PubMed     Abstract available
   
   
   June 2022
6. ALMEKINDERS MM, Bismeijer T, Kumar T, Yang F, et al
   Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.
   Br J Cancer. 2022 Jun 29. pii: 10.1038/s41416-022-01888.
   PubMed     Abstract available
   
   
   
7. LOFLING LL, Stoer NC, Sloan EK, Chang A, et al
   beta-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis.
   Br J Cancer. 2022 Jun 20. pii: 10.1038/s41416-022-01891.
   PubMed     Abstract available
   
   
   
8. BRANTLEY KD, Zeleznik OA, Dickerman BA, Balasubramanian R, et al
   A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses' Health Studies.
   Br J Cancer. 2022 Jun 18. pii: 10.1038/s41416-022-01873.
   PubMed     Abstract available
   
   
   
9. BARTLOME S, Berry CC
   Recent insights into the effects of metabolism on breast cancer cell dormancy.
   Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01869.
   PubMed     Abstract available
   
   
   
10. BAKER JL, Di Meglio A, Gbenou AS, El Mouhebb M, et al
    Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01870.
    PubMed     Abstract available
    
    
    
11. SAURAV S, Manna SK
    Increased expression of Profilin potentiates chemotherapeutic agent-mediated tumour regression.
    Br J Cancer. 2022;126:1410-1420.
    PubMed     Abstract available
    
    
    May 2022
12. MICHMERHUIZEN AR, Lerner LM, Ward C, Pesch AM, et al
    Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer.
    Br J Cancer. 2022 May 26. pii: 10.1038/s41416-022-01849.
    PubMed     Abstract available
    
    
    
13. VALACHIS A, Carlqvist P, Ma Y, Szilcz M, et al
    Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study.
    Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01845.
    PubMed     Abstract available
    
    
    
14. GREENE G, Griffiths R, Han J, Akbari A, et al
    Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system.
    Br J Cancer. 2022 May 2. pii: 10.1038/s41416-022-01830.
    PubMed     Abstract available
    
    
    April 2022
15. JAMES AD, Leslie TK, Kaggie JD, Wiggins L, et al
    Sodium accumulation in breast cancer predicts malignancy and treatment response.
    Br J Cancer. 2022 Apr 25. pii: 10.1038/s41416-022-01802.
    PubMed     Abstract available
    
    
    
16. UMEH-GARCIA M, O'Geen H, Simion C, Gephart MH, et al
    Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer.
    Br J Cancer. 2022 Apr 19. pii: 10.1038/s41416-022-01812.
    PubMed     Abstract available
    
    
    
17. CHAUHAN A, Pal A
    Comments on "Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer".
    Br J Cancer. 2022 Apr 12. pii: 10.1038/s41416-022-01804.
    PubMed    
    
    
    March 2022
18. GAHLAWAT AW, Fahed L, Witte T, Schott S, et al
    Total circulating microRNA level as an independent prognostic marker for risk stratification in breast cancer.
    Br J Cancer. 2022 Mar 22. pii: 10.1038/s41416-022-01756.
    PubMed     Abstract available
    
    
    
19. TOMICZEK-SZWIEC J, Szwiec M, Falco M, Cybulski C, et al
    The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations.
    Br J Cancer. 2022 Mar 7. pii: 10.1038/s41416-022-01770.
    PubMed     Abstract available
    
    
    
20. CLIFT AK, Dodwell D, Lord S, Petrou S, et al
    The current status of risk-stratified breast screening.
    Br J Cancer. 2022;126:533-550.
    PubMed     Abstract available
    
    
    February 2022
21. DE GREGORIO A, Janni W, Friedl TWP, Nitz U, et al
    The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
    Br J Cancer. 2022 Feb 22. pii: 10.1038/s41416-021-01690.
    PubMed     Abstract available
    
    
    
22. MATIKAS A, Kotsakis A, Apostolaki S, Politaki H, et al
    Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer.
    Br J Cancer. 2022 Feb 10. pii: 10.1038/s41416-022-01699.
    PubMed     Abstract available
    
    
    
23. TUTZAUER J, Sjostrom M, Holmberg E, Karlsson P, et al
    Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up.
    Br J Cancer. 2022 Feb 9. pii: 10.1038/s41416-021-01630.
    PubMed     Abstract available
    
    
    
24. WEST CML
    Hypoxia does not predict lack of benefit from adjuvant radiotherapy for patients with early stage breast cancer.
    Br J Cancer. 2022 Feb 9. pii: 10.1038/s41416-022-01707.
    PubMed     Abstract available
    
    
    
25. DE BOO LW, Jozwiak K, Joensuu H, Lindman H, et al
    Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
    Br J Cancer. 2022 Feb 5. pii: 10.1038/s41416-022-01711.
    PubMed     Abstract available
    
    
    
26. DUFFY SW, Seedat F, Kearins O, Press M, et al
    The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation.
    Br J Cancer. 2022 Feb 2. pii: 10.1038/s41416-022-01714.
    PubMed     Abstract available
    
    
    
27. BEDNARZ-KNOLL N, Popeda M, Kryczka T, Kozakiewicz B, et al
    Higher platelet counts correlate to tumour progression and can be induced by intratumoural stroma in non-metastatic breast carcinomas.
    Br J Cancer. 2022;126:464-471.
    PubMed     Abstract available
    
    
    January 2022
28. ZOU R, Loke SY, Tang YC, Too HP, et al
    Development and validation of a circulating microRNA panel for the early detection of breast cancer.
    Br J Cancer. 2022 Jan 10. pii: 10.1038/s41416-021-01593.
    PubMed     Abstract available
    
    
    
29. NAGHAVI-BEHZAD M, Vogsen M, Vester RM, Olsen MMB, et al
    Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT.
    Br J Cancer. 2022 Jan 10. pii: 10.1038/s41416-021-01654.
    PubMed     Abstract available
    
    
    December 2021
30. NYBERG T, Tischkowitz M, Antoniou AC
    BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.
    Br J Cancer. 2021 Dec 28. pii: 10.1038/s41416-021-01675.
    PubMed     Abstract available
    
    
    
31. ADIB E, El Zarif T, Nassar AH, Akl EW, et al
    CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.
    Br J Cancer. 2021 Dec 23. pii: 10.1038/s41416-021-01673.
    PubMed     Abstract available
    
    
    
32. VEITCH Z, Ribnikar D, Tilley D, Tang PA, et al
    No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.
    Br J Cancer. 2021 Dec 20. pii: 10.1038/s41416-021-01676.
    PubMed     Abstract available
    
    
    
33. HARVIE M, Pegington M, Howell SJ, Bundred N, et al
    Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01650.
    PubMed     Abstract available
    
    
    
34. HANNA K, Krzoska E, Shaaban AM, Muirhead D, et al
    Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects.
    Br J Cancer. 2021 Dec 10. pii: 10.1038/s41416-021-01659.
    PubMed     Abstract available
    
    
    November 2021
35. CANELO-AYBAR C, Posso M, Montero N, Sola I, et al
    Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC).
    Br J Cancer. 2021 Nov 26. pii: 10.1038/s41416-021-01521.
    PubMed     Abstract available
    
    
    
36. JAGGUPILLI A, Ly S, Nguyen K, Anand V, et al
    Metabolic stress induces GD2(+) cancer stem cell-like phenotype in triple-negative breast cancer.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01636.
    PubMed     Abstract available
    
    
    
37. SCOTT NP, Teoh EJ, Flight H, Jones BE, et al
    Characterising (18)F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging.
    Br J Cancer. 2021 Nov 18. pii: 10.1038/s41416-021-01623.
    PubMed     Abstract available
    
    
    
38. BYUN D, Hong S, Ryu S, Nam Y, et al
    Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies.
    Br J Cancer. 2021 Nov 12. pii: 10.1038/s41416-021-01625.
    PubMed     Abstract available
    
    
    
39. SUPPAN C, Graf R, Jahn S, Zhou Q, et al
    Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
    Br J Cancer. 2021 Nov 9. pii: 10.1038/s41416-021-01601.
    PubMed     Abstract available
    
    
    
40. ROMUALDO CARDOSO S, Gillespie A, Haider S, Fletcher O, et al
    Functional annotation of breast cancer risk loci: current progress and future directions.
    Br J Cancer. 2021 Nov 5. pii: 10.1038/s41416-021-01612.
    PubMed     Abstract available
    
    
    
41. PARKES EE, Savage KI, Lioe T, Boyd C, et al
    Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
    Br J Cancer. 2021 Nov 2. pii: 10.1038/s41416-021-01599.
    PubMed     Abstract available
    
    
    
42. VAN SEIJEN M, Lips EH, Fu L, Giardiello D, et al
    Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.
    Br J Cancer. 2021;125:1443-1449.
    PubMed     Abstract available
    
    
    October 2021
43. HU J, Lai Y, Huang H, Ramakrishnan S, et al
    TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis.
    Br J Cancer. 2021 Oct 30. pii: 10.1038/s41416-021-01596.
    PubMed     Abstract available
    
    
    
44. GUZMAN-AROCHO YD, Rosenberg SM, Garber JE, Vardeh H, et al
    Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01597.
    PubMed     Abstract available
    
    
    
45. BLACKFORD AL, Childs EJ, Porter N, Petersen GM, et al
    A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01580.
    PubMed     Abstract available
    
    
    
46. KNUTSEN E, Harris AL, Perander M
    Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01588.
    PubMed     Abstract available
    
    
    
47. SI S, Li J, Tewara MA, Li H, et al
    Identifying causality, genetic correlation, priority and pathways of large-scale complex exposures of breast and ovarian cancers.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01576.
    PubMed     Abstract available
    
    
    
48. HERZOG SK, Fuqua SAW
    ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.
    Br J Cancer. 2021 Oct 7. pii: 10.1038/s41416-021-01564.
    PubMed     Abstract available
    
    
    September 2021
49. BIZOT A, Karimi M, Rassy E, Heudel PE, et al
    Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic.
    Br J Cancer. 2021 Sep 29. pii: 10.1038/s41416-021-01555.
    PubMed     Abstract available
    
    
    
50. WANG C, Hu K, Luo C, Deng L, et al
    Cardiovascular mortality among cancer survivors who developed breast cancer as a second primary malignancy.
    Br J Cancer. 2021 Sep 27. pii: 10.1038/s41416-021-01549.
    PubMed     Abstract available
    
    
    
51. PARK B, Kim S, Kim H, Cha C, et al
    Associations between obesity, metabolic health, and the risk of breast cancer in East Asian women.
    Br J Cancer. 2021 Sep 22. pii: 10.1038/s41416-021-01540.
    PubMed     Abstract available
    
    
    
52. MONDAL M, Conole D, Nautiyal J, Tate EW, et al
    UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology.
    Br J Cancer. 2021 Sep 8. pii: 10.1038/s41416-021-01516.
    PubMed     Abstract available
    
    
    
53. DONAT-VARGAS C, Guerrero-Zotano A, Casas A, Baena-Canada JM, et al
    Trajectories of alcohol consumption during life and the risk of developing breast cancer.
    Br J Cancer. 2021 Sep 6. pii: 10.1038/s41416-021-01492.
    PubMed     Abstract available
    
    
    
54. FORTIN J, Leblanc M, Elgbeili G, Cordova MJ, et al
    The mental health impacts of receiving a breast cancer diagnosis: A meta-analysis.
    Br J Cancer. 2021 Sep 4. pii: 10.1038/s41416-021-01542.
    PubMed     Abstract available
    
    
    
55. MUKAI H, Uemura Y, Akabane H, Watanabe T, et al
    Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer.
    Br J Cancer. 2021 Sep 3. pii: 10.1038/s41416-021-01531.
    PubMed     Abstract available
    
    
    
56. CHATZIPLI A, Bonnefoi H, MacGrogan G, Sentis J, et al
    Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer.
    Br J Cancer. 2021 Sep 3. pii: 10.1038/s41416-021-01526.
    PubMed     Abstract available
    
    
    
57. GWILI N, Jones SJ, Amri WA, Carr IM, et al
    Transcriptome profiles of stem-like cells from primary breast cancers allow identification of ITGA7 as a predictive marker of chemotherapy response.
    Br J Cancer. 2021;125:983-993.
    PubMed     Abstract available
    
    
    
58. LIU Z, Thong MSY, Doege D, Koch-Gallenkamp L, et al
    Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany.
    Br J Cancer. 2021;125:877-883.
    PubMed     Abstract available
    
    
    
59. BURNSIDE ES, Warren LM, Myles J, Wilkinson LS, et al
    Quantitative breast density analysis to predict interval and node-positive cancers in pursuit of improved screening protocols: a case-control study.
    Br J Cancer. 2021;125:884-892.
    PubMed     Abstract available
    
    
    August 2021
60. MARTI JLG, Beckwitt CH, Clark AM, Wells A, et al
    Atorvastatin facilitates chemotherapy effects in metastatic triple-negative breast cancer.
    Br J Cancer. 2021 Aug 30. pii: 10.1038/s41416-021-01529.
    PubMed     Abstract available
    
    
    
61. KAUR P, Porras TB, Colombo A, Ring A, et al
    Identification of putative actionable alterations in clinically relevant genes in breast cancer.
    Br J Cancer. 2021 Aug 28. pii: 10.1038/s41416-021-01522.
    PubMed     Abstract available
    
    
    
62. ATTARAN S, Skoko JJ, Hopkins BL, Wright MK, et al
    Peroxiredoxin-1 Tyr194 phosphorylation regulates LOX-dependent extracellular matrix remodelling in breast cancer.
    Br J Cancer. 2021 Aug 13. pii: 10.1038/s41416-021-01510.
    PubMed     Abstract available
    
    
    
63. JORGENSEN N, Hviid TVF, Nielsen LB, Sonderstrup IMH, et al
    Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.
    Br J Cancer. 2021 Aug 7. pii: 10.1038/s41416-021-01514.
    PubMed     Abstract available
    
    
    
64. PARK HA, Neumeyer S, Michailidou K, Bolla MK, et al
    Mendelian randomisation study of smoking exposure in relation to breast cancer risk.
    Br J Cancer. 2021 Aug 2. pii: 10.1038/s41416-021-01432.
    PubMed     Abstract available
    
    
    
65. AMIRI SOURI E, Chenoweth A, Cheung A, Karagiannis SN, et al
    Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer.
    Br J Cancer. 2021;125:748-758.
    PubMed     Abstract available
    
    
    July 2021
66. HICKEY TE, Dwyer AR, Tilley WD
    Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer.
    Br J Cancer. 2021 Jul 22. pii: 10.1038/s41416-021-01478.
    PubMed     Abstract available
    
    
    
67. LOVERO D, D'Oronzo S, Palmirotta R, Cafforio P, et al
    Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases.
    Br J Cancer. 2021 Jul 16. pii: 10.1038/s41416-021-01481.
    PubMed     Abstract available
    
    
    
68. WANG Y, Ye F, Liang Y, Yang Q, et al
    Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies.
    Br J Cancer. 2021 Jul 5. pii: 10.1038/s41416-021-01424.
    PubMed     Abstract available
    
    
    
69. JOSEPH R, Soundararajan R, Vasaikar S, Yang F, et al
    CD8(+) T cells inhibit metastasis and CXCL4 regulates its function.
    Br J Cancer. 2021;125:176-189.
    PubMed     Abstract available
    
    
    June 2021
70. DAVE RV, Kim B, Courtney A, O'Connell R, et al
    Publisher Correction: Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study.
    Br J Cancer. 2021 Jun 23. pii: 10.1038/s41416-021-01465.
    PubMed    
    
    
    
71. BURRIS HA, Chan A, Bardia A, Thaddeus Beck J, et al
    Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
    Br J Cancer. 2021 Jun 22. pii: 10.1038/s41416-021-01415.
    PubMed     Abstract available
    
    
    
72. AZAM S, Eriksson M, Sjolander A, Gabrielson M, et al
    Mammographic microcalcifications and risk of breast cancer.
    Br J Cancer. 2021 Jun 14. pii: 10.1038/s41416-021-01459.
    PubMed     Abstract available
    
    
    
73. CHEN F, Han Y, Kang Y
    Bone marrow niches in the regulation of bone metastasis.
    Br J Cancer. 2021;124:1912-1920.
    PubMed     Abstract available
    
    
    May 2021
74. DAVIDSON BA, Croessmann S, Park BH
    The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer.
    Br J Cancer. 2021 May 26. pii: 10.1038/s41416-021-01422.
    PubMed     Abstract available
    
    
    
75. GIANNAKEAS V, Lim DW, Narod SA
    The risk of contralateral breast cancer: a SEER-based analysis.
    Br J Cancer. 2021 May 26. pii: 10.1038/s41416-021-01417.
    PubMed     Abstract available
    
    
    
76. GATHANI T, Reeves G, Broggio J, Barnes I, et al
    Ethnicity and the tumour characteristics of invasive breast cancer in over 116,500 women in England.
    Br J Cancer. 2021 May 26. pii: 10.1038/s41416-021-01409.
    PubMed     Abstract available
    
    
    
77. VAIDYA JS, Bulsara M, Baum M, Wenz F, et al
    New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer.
    Br J Cancer. 2021 May 25. pii: 10.1038/s41416-021-01440.
    PubMed     Abstract available
    
    
    
78. ENGVALL K, Green H, Fredriksson M, Avall-Lundqvist E, et al
    Persistent neuropathy among early-stage breast cancer survivors in a population-based cohort.
    Br J Cancer. 2021 May 20. pii: 10.1038/s41416-021-01429.
    PubMed     Abstract available
    
    
    
79. OKINES AFC, Kipps E, Irfan T, Coakley M, et al
    Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experience.
    Br J Cancer. 2021 May 20. pii: 10.1038/s41416-021-01428.
    PubMed     Abstract available
    
    
    
80. FARVID MS, Barnett JB, Spence ND
    Fruit and vegetable consumption and incident breast cancer: a systematic review and meta-analysis of prospective studies.
    Br J Cancer. 2021 May 18. pii: 10.1038/s41416-021-01373.
    PubMed     Abstract available
    
    
    
81. PAN K, Aragaki AK, Neuhouser ML, Simon MS, et al
    Low-fat dietary pattern and breast cancer mortality by metabolic syndrome components: a secondary analysis of the Women's Health Initiative (WHI) randomised trial.
    Br J Cancer. 2021 May 18. pii: 10.1038/s41416-021-01379.
    PubMed     Abstract available
    
    
    
82. ROBERTO A, Colombo C, Candiani G, Satolli R, et al
    Correction: A dynamic web-based decision aid to improve informed choice in organised breast cancer screening. A pragmatic randomized trial in Italy.
    Br J Cancer. 2021 May 11. pii: 10.1038/s41416-021-01437.
    PubMed    
    
    
    
83. RING A, Battisti NML, Reed MWR, Herbert E, et al
    Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer.
    Br J Cancer. 2021 May 10. pii: 10.1038/s41416-021-01388.
    PubMed     Abstract available
    
    
    
84. AMADOU A, Freisling H, Jenab M, Tsilidis KK, et al
    Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
    Br J Cancer. 2021;124:1882-1890.
    PubMed     Abstract available
    
    
    
85. BARTSCH R, Singer CF, Pfeiler G, Hubalek M, et al
    Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.
    Br J Cancer. 2021;124:1795-1802.
    PubMed     Abstract available
    
    
    April 2021
86. PARK YM, Sandler DP
    Making sense of associations between type 2 diabetes, metformin, and breast cancer risk.
    Br J Cancer. 2021 Apr 28. pii: 10.1038/s41416-021-01372.
    PubMed     Abstract available
    
    
    
87. KO SM, Lee J, Bae SJ, Baik SJ, et al
    Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients.
    Br J Cancer. 2021 Apr 19. pii: 10.1038/s41416-021-01391.
    PubMed     Abstract available
    
    
    
88. YUAN WH, Hsu HC, Wu CH
    Reply to Comment on "Supplemental breast cancer-screening ultrasonography in women with dense breasts: a systematic review and meta-analysis".
    Br J Cancer. 2021 Apr 19. pii: 10.1038/s41416-021-01349.
    PubMed    
    
    
    
89. TIN TIN S, Reeves GK, Key TJ
    Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank.
    Br J Cancer. 2021 Apr 16. pii: 10.1038/s41416-021-01392.
    PubMed     Abstract available
    
    
    
90. DAVE RV, Kim B, Courtney A, O'Connell R, et al
    Correction: Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01378.
    PubMed    
    
    
    
91. JAYARAJ R, Shaw P, Shetty S, Kumaraswamy C, et al
    Comment on "Supplemental breast cancer-screening ultrasonography in women with dense breasts: a systematic review and meta-analysis".
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01348.
    PubMed    
    
    
    
92. BINES J, Clark E, Barton C, Restuccia E, et al
    Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01323.
    PubMed     Abstract available
    
    
    
93. LUOND F, Tiede S, Christofori G
    Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression.
    Br J Cancer. 2021 Apr 6. pii: 10.1038/s41416-021-01328.
    PubMed     Abstract available
    
    
    
94. KREGTING LM, Kaljouw S, de Jonge L, Jansen EEL, et al
    Effects of cancer screening restart strategies after COVID-19 disruption.
    Br J Cancer. 2021;124:1516-1523.
    PubMed     Abstract available
    
    
    
95. WALLER CF, Mobius J, Fuentes-Alburo A
    Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice.
    Br J Cancer. 2021;124:1346-1352.
    PubMed     Abstract available
    
    
    March 2021
96. DAVE RV, Kim B, Courtney A, O'Connell R, et al
    Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study.
    Br J Cancer. 2021 Mar 25. pii: 10.1038/s41416-020-01234.
    PubMed     Abstract available
    
    
    
97. RAKHA EA, Miligy IM, Quinn CM, Provenzano E, et al
    Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio >/=2.0, HER2 copy number <4.0 signals/cell) cases.
    Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01351.
    PubMed     Abstract available
    
    
    
98. KROL I, Schwab FD, Carbone R, Ritter M, et al
    Detection of clustered circulating tumour cells in early breast cancer.
    Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01327.
    PubMed     Abstract available
    
    
    
99. FARVID MS, Spence ND, Rosner BA, Willett WC, et al
    Post-diagnostic coffee and tea consumption and breast cancer survival.
    Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01277.
    PubMed     Abstract available
    
    
    
100. GRIS-OLIVER A, Ibrahim YH, Rivas MA, Garcia-Garcia C, et al
     PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
     Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01293.
     PubMed     Abstract available
     
     
     
101. JOBARD E, Dossus L, Baglietto L, Fornili M, et al
     Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: a case-control study nested within the French E3N cohort.
     Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01304.
     PubMed     Abstract available
     
     
     
102. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
     The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
     Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
     PubMed     Abstract available
     
     
     
103. PAI BELLARE G, Saha B, Patro BS
     Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition.
     Br J Cancer. 2021;124:1260-1274.
     PubMed     Abstract available
     
     
     
104. BADVE SS, Cho S, Gokmen-Polar Y, Sui Y, et al
     Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast.
     Br J Cancer. 2021;124:1150-1159.
     PubMed     Abstract available
     
     
     
105. WINKLER C, Armenia J, Jones GN, Tobalina L, et al
     SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
     Br J Cancer. 2021;124:951-962.
     PubMed     Abstract available
     
     
     
106. ZENG Y, Gao W, Chen X, Shen K, et al
     Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
     Br J Cancer. 2021;124:975-981.
     PubMed     Abstract available
     
     
     
107. SHAABAN AM, Hilton B, Clements K, Provenzano E, et al
     Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project.
     Br J Cancer. 2021;124:1009-1017.
     PubMed     Abstract available
     
     
     February 2021
108. EVANS DG, Phillips KA, Milne RL, Fruscio R, et al
     Survival from breast cancer in women with a BRCA2 mutation by treatment.
     Br J Cancer. 2021 Feb 18. pii: 10.1038/s41416-020-01164.
     PubMed     Abstract available
     
     
     
109. GIORGI ROSSI P, Lebeau A, Canelo-Aybar C, Saz-Parkinson Z, et al
     Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
     Br J Cancer. 2021 Feb 18. pii: 10.1038/s41416-020-01247.
     PubMed     Abstract available
     
     
     
110. LAAS E, Labrosse J, Hamy AS, Benchimol G, et al
     Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore.
     Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-020-01251.
     PubMed     Abstract available
     
     
     
111. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
     Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
     Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
     PubMed     Abstract available
     
     
     
112. REYES-RUIZ A, Calvillo-Rodriguez KM, Martinez-Torres AC, Rodriguez-Padilla C, et al
     The bovine dialysable leukocyte extract IMMUNEPOTENT CRP induces immunogenic cell death in breast cancer cells leading to long-term antitumour memory.
     Br J Cancer. 2021 Feb 3. pii: 10.1038/s41416-020-01256.
     PubMed     Abstract available
     
     
     
113. VAIDYA JS, Bulsara M, Baum M, Tobias JS, et al
     Single-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment.
     Br J Cancer. 2021 Feb 2. pii: 10.1038/s41416-020-01233.
     PubMed     Abstract available
     
     
     
114. JOHNSON N, Maguire S, Morra A, Kapoor PM, et al
     CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers.
     Br J Cancer. 2021;124:842-854.
     PubMed     Abstract available
     
     
     
115. MARONI R, Massat NJ, Parmar D, Dibden A, et al
     A case-control study to evaluate the impact of the breast screening programme on mortality in England.
     Br J Cancer. 2021;124:736-743.
     PubMed     Abstract available
     
     
     January 2021
116. SESTAK I, Blake G, Patel R, Cuzick J, et al
     Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial.
     Br J Cancer. 2021 Jan 22. pii: 10.1038/s41416-020-01228.
     PubMed     Abstract available
     
     
     
117. CABEL L, Berger F, Cottu P, Loirat D, et al
     Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial.
     Br J Cancer. 2021 Jan 21. pii: 10.1038/s41416-020-01227.
     PubMed     Abstract available
     
     
     
118. BROAD RV, Jones SJ, Teske MC, Wastall LM, et al
     Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy.
     Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01226.
     PubMed     Abstract available
     
     
     
119. OTSUJI K, Sasaki T, Tanabe M, Seto Y, et al
     Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
     Br J Cancer. 2021;124:466-473.
     PubMed     Abstract available
     
     
     
120. CHEN JY, Li CF, Lai YS, Hung WC, et al
     Lysine demethylase 2A expression in cancer-associated fibroblasts promotes breast tumour growth.
     Br J Cancer. 2021;124:484-493.
     PubMed     Abstract available
     
     
     December 2020
121. ANEMONE A, Consolino L, Conti L, Irrera P, et al
     Tumour acidosis evaluated in vivo by MRI-CEST pH imaging reveals breast cancer metastatic potential.
     Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01173.
     PubMed     Abstract available
     
     
     
122. ROLVER MG, Pedersen SF
     Putting Warburg to work: how imaging of tumour acidosis could help predict metastatic potential in breast cancer.
     Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01171.
     PubMed     Abstract available
     
     
     
123. DUSTIN D, Gu G, Beyer AR, Herzog SK, et al
     RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
     Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01174.
     PubMed     Abstract available
     
     
     
124. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
     First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
     Br J Cancer. 2020;123:1730-1736.
     PubMed     Abstract available
     
     
     November 2020
125. BAILLEUX C, Eberst L, Bachelot T
     Treatment strategies for breast cancer brain metastases.
     Br J Cancer. 2020 Nov 30. pii: 10.1038/s41416-020-01175.
     PubMed     Abstract available
     
     
     
126. GATHANI T, Clayton G, MacInnes E, Horgan K, et al
     The COVID-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 2020.
     Br J Cancer. 2020 Nov 30. pii: 10.1038/s41416-020-01182.
     PubMed     Abstract available
     
     
     
127. RIGGIO AI, Varley KE, Welm AL
     The lingering mysteries of metastatic recurrence in breast cancer.
     Br J Cancer. 2020 Nov 26. pii: 10.1038/s41416-020-01161.
     PubMed     Abstract available
     
     
     
128. DWYER AR, Truong TH, Kerkvliet CP, Paul KV, et al
     Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer.
     Br J Cancer. 2020 Nov 4. pii: 10.1038/s41416-020-01094.
     PubMed     Abstract available
     
     
     
129. TAILOR D, Going CC, Resendez A, Kumar V, et al
     Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer.
     Br J Cancer. 2020 Nov 3. pii: 10.1038/s41416-020-01137.
     PubMed     Abstract available
     
     
     
130. KALAW E, Lim M, Kutasovic JR, Sokolova A, et al
     Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1.
     Br J Cancer. 2020;123:1665-1672.
     PubMed     Abstract available
     
     
     
131. LI YY, Gao LJ, Zhang YX, Liu SJ, et al
     Bisphosphonates and risk of cancers: a systematic review and meta-analysis.
     Br J Cancer. 2020;123:1570-1581.
     PubMed     Abstract available
     
     
     
132. MILIGY IM, Toss MS, Shiino S, Oni G, et al
     The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ.
     Br J Cancer. 2020;123:1513-1520.
     PubMed     Abstract available
     
     
     October 2020
133. MOROTTI M, Zois CE, El-Ansari R, Craze ML, et al
     Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer.
     Br J Cancer. 2020 Oct 8. pii: 10.1038/s41416-020-01113.
     PubMed     Abstract available
     
     
     
134. ZHENG G, Sundquist J, Sundquist K, Ji J, et al
     Association of post-diagnostic use of cholera vaccine with survival outcome in breast cancer patients.
     Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01108.
     PubMed     Abstract available
     
     
     
135. PEDROZA DA, Rajamanickam V, Subramani R, Bencomo A, et al
     Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling.
     Br J Cancer. 2020;123:1326-1335.
     PubMed     Abstract available
     
     
     September 2020
136. BEDDOK A, Xu HP, Henry AA, Porte B, et al
     Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature.
     Br J Cancer. 2020;123:905-908.
     PubMed     Abstract available
     
     
     
137. WANG L, Wang Q, Xu P, Fu L, et al
     YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer.
     Br J Cancer. 2020;123:1000-1011.
     PubMed     Abstract available
     
     
     
138. DE MUNCK L, Siesling S, Fracheboud J, den Heeten GJ, et al
     Impact of mammographic screening and advanced cancer definition on the percentage of advanced-stage cancers in a steady-state breast screening programme in the Netherlands.
     Br J Cancer. 2020;123:1191-1197.
     PubMed     Abstract available
     
     
     
139. AMBROISE G, Yu TT, Zhang B, Kacal M, et al
     Systematic analysis reveals a functional role for STAMBPL1 in the epithelial-mesenchymal transition process across multiple carcinomas.
     Br J Cancer. 2020;123:1164-1177.
     PubMed     Abstract available
     
     
     July 2020
140. BRUNELLE CL, Taghian AG
     Lymphoedema screening: setting the standard.
     Br J Cancer. 2020;123:1-2.
     PubMed     Abstract available
     
     
     
141. METCALFE KA, Price MA, Mansfield C, Hallett DC, et al
     Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
     Br J Cancer. 2020;123:268-274.
     PubMed     Abstract available
     
     
     
142. MCCARTNEY A, Malorni L
     Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors.
     Br J Cancer. 2020;123:176-177.
     PubMed     Abstract available
     
     
     
143. BUNDRED N, Foden P, Todd C, Morris J, et al
     Increases in arm volume predict lymphoedema and quality of life deficits after axillary surgery: a prospective cohort study.
     Br J Cancer. 2020;123:17-25.
     PubMed     Abstract available
     
     
     June 2020
144. SUGANO T, Yoshida M, Masuda M, Ono M, et al
     Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma.
     Br J Cancer. 2020;122:1811-1817.
     PubMed     Abstract available
     
     
     May 2020
145. TOSS MS, Abidi A, Lesche D, Joseph C, et al
     The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
     Br J Cancer. 2020;122:1496-1506.
     PubMed     Abstract available
     
     
     February 2020
146. ROBERTS C, Strauss VY, Kopijasz S, Gourley C, et al
     Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
     Br J Cancer. 2020;122:483-490.
     PubMed     Abstract available
     
     
     
147. VISSIO E, Metovic J, Osella-Abate S, Bertero L, et al
     Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling.
     Br J Cancer. 2020;122:382-387.
     PubMed     Abstract available
     
     
     
148. EVANS DG, Edwards M, Duffy SW, Tischkowitz M, et al
     Sporadic implementation of UK familial mammographic surveillance guidelines 15 years after original publication.
     Br J Cancer. 2020;122:329-332.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: